POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare bone marrow cancer: drug combo trial launches
Disease control Recruiting nowThis early-stage study tests whether adding pelabresib to the standard drug ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow cancer. Only 6 participants will receive the combination to check for side effects and measure drug levels. The goal is to fi…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 11:33 UTC